RushDATA™ Delivers Wet-Lab Validation for AI-Designed Antibodies from Molence Bio’s Mol-1
RushDATA™ Delivers Wet-Lab Validation for AI-Designed Antibodies from Molence Bio’s Mol-1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biointron Biological USA Inc. ("Biointron") is proud to have supported Molence Bio's Mol-1 project. Mol-1 matches the performance of the leading closed-source model IsoDDE in antibody-antigen structure prediction and can design functional nanobodies from scratch. To show those designs can become real drug candidates, Biointron ran the developability assays using RushDATA™, our wet-lab validation service for AI-designed antibodies.
The results: 23 of 30 AI-designed candidates met at least three of four developability criteria.
Wet-Lab Validation by Biointron
An AI-designed antibody needs lab data to prove it can become a drug. Biointron ran the developability panel on Molence Bio's VHH-Fc candidates, measuring properties that predict manufacturability and safety, including hydrophobicity, thermal stability, self-interaction, and non-specific binding.
Each assay was benchmarked against Biointron reference antibodies, including infliximab, bevacizumab, bococizumab, gantenerumab and trastuzumab, so the designs could be compared directly with approved and clinical-stage antibodies.
Closing the Loop Between AI and the Lab
RushDATA™ is Biointron’s wet-lab validation service for AI-designed antibodies, combining a capacity of 10,000+ antibodies per day with sequence-to-data turnaround in as little as 2 days with cell-free expression or 3 days with CHO expression.
The service offers multi-point binding affinity measurements by BLI or SPR, alongside developability profiling using DSF, PSR-BVP, and AC-SINS. Results are delivered as structured, model-ready datasets with API access, allowing experimental findings to feed directly into the next round of AI-guided design.
Why It Matters Now
AI can now generate antibody binders at scale. The next challenge is proving which designs work in the lab and behave like drugs. Mol-1 shows what happens when a strong open model meets high-quality experimental data, and Biointron is proud to provide that data.
Biointron congratulates Molence Bio on the launch of Mol-1 and looks forward to supporting the researchers who build on it.
About Biointron
Founded in 2012, Biointron is a global antibody discovery CRO trusted by 3,000+ organizations in 20+ countries and regions, including top 20 pharma companies. Our RushDATA™ platform generates wet-lab data for AI-designed antibodies at scale, expressing 10,000+ antibodies a day and delivering binding and developability results in as little as 2 days, ready to feed your models via API. We also offer end-to-end antibody services from discovery to large-scale production. Several partner projects using our CHOK1BN cell line have entered multicenter international clinical trials successfully.
Learn more about RushDATA™: https://www.biointron.com/antibody-production/rushdata.html
About Molence Bio
Molence Bio is an AI-native biotech built on their own biomolecular foundation models. Their biologists, chemists, and AI researchers work side by side to advance these models and apply them to drug discovery: unlocking targets long considered undruggable, designing better molecules, and building a pipeline of therapies for unmet medical needs.
Access the model weights: https://github.com/molence/Mol-1
Contacts
Biointron
+1 (732) 790-8340
info@biointron.com
20 University Road, Suite 500, Cambridge, MA 02138
Media contact: Mia Deng

